Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | See Remarks | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,142 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 23,116 · Balance 133,142 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.52 · Expires 2036-04-16 | Direct | 79,936 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 79,936 · Balance 79,936 F3: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 20, 2026 21:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 79,936 | $0.00 Strike: $24.52 | $0.00 |
DisclosureSEC source: 0001193125-26-164289 · ownership.xml · derivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,936 Underlying: Common Stock · 79,936 shares Expires 2036-04-16 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 23,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164289 · ownership.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,142 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 00:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 10,029 | $22.80 | $228,661.20 |
DisclosureSEC source: 0001193125-26-089287 · ownership.xml · nonDerivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,026 F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range F4 · balance_after: Includes 490 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025 F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 00:09 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 11,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089287 · ownership.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,565 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 31 | $42.92 | $1,330.52 |
DisclosureSEC source: 0000950170-25-032785 · ownership.xml · nonDerivative · entry 4 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,428 F5 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F6 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F7 · balance_after: Includes 693 shares acquired under the Company's Amended & Restated Employee Stock Purchase Plan on April 30, 2024 Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 14,439 | $42.10 | $607,881.90 |
DisclosureSEC source: 0000950170-25-032785 · ownership.xml · nonDerivative · entry 3 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,766 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 26,074 | $0.00 Strike: $42.92 | $0.00 |
DisclosureSEC source: 0000950170-25-032785 · ownership.xml · derivative · entry 5 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,074 Underlying: Commmon Stock · 26,074 shares Expires 2035-03-01 F8 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 18,443 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032785 · ownership.xml · nonDerivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,205 F2 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 14,494 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032785 · ownership.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,762 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 31,400 | $0.00 Strike: $53.69 | $0.00 |
DisclosureSEC source: 0000950170-24-026648 · ownership.xml · derivative · entry 5 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,400 Underlying: Common Stock · 31,400 shares Expires 2034-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,173 | $53.76 | $224,340.48 |
DisclosureSEC source: 0000950170-24-026648 · ownership.xml · nonDerivative · entry 4 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,268 F4 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 60 | $53.69 | $3,221.40 |
DisclosureSEC source: 0000950170-24-026648 · ownership.xml · nonDerivative · entry 3 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,441 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 957 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026648 · ownership.xml · nonDerivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,501 F2 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 17,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026648 · ownership.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,544 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document |
| May 18, 2023 Filed May 19, 2023 17:54 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,012 | $50.00 | $100,600.00 |
DisclosureSEC source: 0001209191-23-030931 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,744 F1 · shares: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. F2 · balance_after: Includes 596 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Grant3/1/2023 · Derivative | 39,400 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-23-016042 · doc4.xml · derivative · entry 5 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,400 Underlying: Common Stock · 39,400 shares Expires 2033-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Disposition to issuerCommon Stock | 4,014 | $45.65 | $183,239.10 |
DisclosureSEC source: 0001209191-23-016042 · doc4.xml · nonDerivative · entry 4 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,160 F4 · shares: Shares were acquired upon the partial vesting of a previously reported RSU and were sold to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,755 | $45.26 | $169,951.30 |
DisclosureSEC source: 0001209191-23-016042 · doc4.xml · nonDerivative · entry 3 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,174 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016042 · doc4.xml · nonDerivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,929 F2 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016042 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,929 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 24,900 | $0.00 Strike: $67.37 | $0.00 |
DisclosureSEC source: 0001209191-22-015823 · doc4.xml · derivative · entry 3 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 24,900 shares Expires 2032-03-01 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015823 · doc4.xml · nonDerivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,266 F2 · shares: Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,498 | $66.62 | $299,656.76 |
DisclosureSEC source: 0001209191-22-015823 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,266 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| October 14, 2021 Filed Oct 18, 2021 22:41 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 358 | $81.14 | $29,048.12 |
DisclosureSEC source: 0001209191-21-060748 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,764 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2021 Filed May 10, 2021 22:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 363 | $113.69 | $41,269.47 |
DisclosureSEC source: 0001209191-21-031387 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,122 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes 248 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2021. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $142.47 | $0.00 |
DisclosureSEC source: 0001209191-21-017561 · doc4.xml · derivative · entry 4 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 6,198 | $138.17 | $856,377.66 |
DisclosureSEC source: 0001209191-21-017561 · doc4.xml · nonDerivative · entry 3 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,237 F3 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.17 to $138.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 4,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017561 · doc4.xml · nonDerivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,435 F2 · shares: Represents 1,530 shares of common stock and 3,106 RSUs into which previously granted performance stock units were converted on March 1, 2021 upon certification of the performance metric. The RSUs will fully vest on March 1, 2022. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017561 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,799 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 23:19 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 262 | $88.00 | $23,056.00 |
DisclosureSEC source: 0001209191-20-055175 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,299 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 21:55 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,780 | $94.47 | $262,626.60 |
DisclosureSEC source: 0001209191-20-054712 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,561 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.91 to $95.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 18:20 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 262 | $69.38 | $18,177.56 |
DisclosureSEC source: 0001209191-20-033887 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,341 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 612 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2020. Read SEC document |
| May 06, 2020 Filed May 8, 2020 23:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 248 | $66.26 | $16,432.48 |
DisclosureSEC source: 0001209191-20-028107 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,991 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 19, 2020 Filed Apr 21, 2020 19:37 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 248 | $58.57 | $14,525.36 |
DisclosureSEC source: 0001209191-20-025192 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,239 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $56.08 | $0.00 |
DisclosureSEC source: 0001209191-20-015750 · doc4.xml · derivative · entry 4 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 3,085 | $56.08 | $173,006.80 |
DisclosureSEC source: 0001209191-20-015750 · doc4.xml · nonDerivative · entry 3 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,487 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015750 · doc4.xml · nonDerivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,572 F3 · shares: Represents 1,859 shares of common stock and 3,775 RSUs into which previously granted performance stock units were converted on March 1, 2020 upon certification of the performance metric. The RSUs will fully vest on March 1, 2021. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015750 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,938 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 23:27 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053323 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,138 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on October 14, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| July 16, 2019 Filed Jul 17, 2019 21:02 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 649 | $59.17 | $38,401.33 |
DisclosureSEC source: 0001209191-19-042404 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,704 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 22:54 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 260 | $54.93 | $14,281.80 |
DisclosureSEC source: 0001209191-19-034545 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,353 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2019 Filed May 7, 2019 23:04 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-028099 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,613 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on May 6, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 461 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2019. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 22:29 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 248 | $64.43 | $15,978.64 |
DisclosureSEC source: 0001209191-19-025616 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,718 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 05, 2019 Filed Apr 17, 2019 21:56 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 722 | $65.52 | $47,305.44 |
DisclosureSEC source: 0001209191-19-025109 · doc4a.xml · nonDerivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,966 F4 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $67.55 | $0.00 |
DisclosureSEC source: 0001209191-19-015747 · doc4.xml · derivative · entry 3 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2029-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 701 | $67.55 | $47,352.55 |
DisclosureSEC source: 0001209191-19-015747 · doc4.xml · nonDerivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,986 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015747 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,687 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 6 shares acquired under the Company's 2014 Employee Stock Purchase Plan. Read SEC document |
| March 01, 2019 Filed Apr 17, 2019 21:56 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $67.55 | $0.00 |
DisclosureSEC source: 0001209191-19-025109 · doc4a.xml · derivative · entry 3 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2029-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2019 Filed Apr 17, 2019 21:56 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025109 · doc4a.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,688 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 6 shares acquired under the Company's 2014 Employee Stock Purchase Plan. Read SEC document |
| July 16, 2018 Filed Jul 16, 2018 23:54 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 649 | $84.35 | $54,743.15 |
DisclosureSEC source: 0001209191-18-042706 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,681 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.